Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.

Immunotherapy - 1 Oct 2018

Tarhini Ahmad, Benedict Agnes, McDermott David, Rao Sumati, Ambavane Apoorva, Gupte-Singh Komal, Sabater Javier, Ritchings Corey, Aponte-Ribero Valerie, Regan Meredith M, Atkins Michael

Abstract excerpt

AIM: To evaluate the cost-effectiveness of treatment sequences with checkpoint inhibitors in patients with BRAF wild-type melanoma. MATERIALS & METHODS: Using a discrete event simulation model, cost and health outcomes were estimated. Pooled data from CheckMate 067/069 trials were used to calculate survival outcomes including treatment-free interval extrapolated over a patient's lifetime. Costs accounted for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CTLA-4 Antigen

Share to Health Care Costs

Share to Ipilimumab

Share to Models, Economic

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Source

Identifiers

PMID: 30175642
DOI: 10.2217/imt-2018-0085

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.PMID 30175642Read ↗

Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF -Mutant Advanced MelanomaSemantic proximity Read ↗

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.Semantic proximity Read ↗

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.Semantic proximity Read ↗

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.Semantic proximity Read ↗

Cost-Effectiveness of Immune Checkpoint Inhibition and Targeted Treatment in Combination as Adjuvant Treatment of Patient with BRAF-Mutant Advanced MelanomaSemantic proximity Read ↗

Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy.Semantic proximity Read ↗

Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.Semantic proximity Read ↗

Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.Semantic proximity Read ↗

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.Semantic proximity Read ↗

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.Semantic proximity Read ↗

First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.